乾癬治療の市場規模、シェア、予測、動向分析、治療別、疾患別-2031年までの世界予測

乾癬治療市場は、2024年から2031年までのCAGR 9.8%で、2031年には350億7,000万米ドルに達すると予測されます。

当レポートでは、徹底的な2次調査と1次調査、市場シナリオの詳細な分析に基づき、主要な市場促進要因・課題・機会・動向について論じています。

この市場の成長は、乾癬の高負担、治療オプションと診断方法の進歩、疾患発症のより良い理解、高齢化人口における乾癬の有病率の上昇などの要因によって牽引されます。さらに、乾癬に対する認識の高まり、併用療法の利用率の上昇、乾癬に関する研究の進行は、市場成長の機会を生み出すと期待されています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場洞察

• 概要
• 市場成長の要因
  • 促進要因
    • 乾癬の高い負担
    • 治療法の進歩
    • 乾癬診断の改善
    • 乾癬にかかりやすい高齢者
  • 抑制要因
    • 高い乾癬治療費
    • 薬の副作用
  • 機会
    • 乾癬に対する意識の高まり
    • 治療における併用療法の増加
    • 乾癬に関する調査の増加
  • 課題
    • 医薬品の厳しい規制と承認プロセス
• 動向
  • 標的治療薬
  • ステロイドフリー外用薬
• 要因分析
• 製品パイプライン分析
• 規制分析
• ポーターのファイブフォース分析
• 資金調達と投資分析

第5章 乾癬治療市場：検査タイプ別評価

• 概要
• 生物学的製剤
  • TNF阻害薬
    • インフリキシマブ
    • アダリムマブ
    • エタネルセプト
    • その他のTNF阻害薬
  • インターロイキン阻害薬
    • グセルクマブ
    • リサンキズマブ
    • チルドラキズマブ
  • その他の生物学的製剤
• 局所治療薬
  • 副腎皮質ステロイド
    • ヒドロコルチゾン
    • デソニド
    • ベタメタゾン
    • その他の副腎皮質ステロイド
  • ビタミンDアナログ
    • カルシトロール
    • カルシポトリオール
    • タカルシトール
  • レチノイド
  • カルシニューリン阻害薬
• 全身治療薬
  • メトトレキサート
  • シクロスポリン
  • アシトレチン
  • その他の全身治療薬

第6章 乾癬治療市場：疾患タイプ別評価

• 概要
• プラーク乾癬
• 乾癬性関節炎
• その他のタイプ

第7章 乾癬治療市場：投与経路別評価

• 概要
• 経口剤
• 局所
• 注射剤

第8章 乾癬治療市場：流通チャネル別評価

• 概要
• 病院薬局
• 小売薬局
• オンライン/eコマースプラットフォーム

第9章 乾癬治療市場：地域別評価

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • オランダ
  • スイス
  • ポーランド
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • ニュージーランド
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
• 中東・アフリカ

第10章 競合分析

• 概要
• 主要成長戦略
• 競合ベンチマーキング
• 競合ダッシュボード
  • 業界リーダー
  • 市場差別化要因
  • 先行企業
  • 新興企業
• 主要企業別市場シェア分析/市場ランキング分析（2023年）

第11章 企業プロファイル（事業概要、財務概要、製品ポートフォリオ、戦略的展開、SWOT分析*）。

• AbbVie Inc.（U.S.）
• AstraZenca Plc（U.K.）
• Boehringer Ingelheim（Germany）
• Celgene Corporation（U.S.）
• Eli Lilly and Company（U.S.）
• Johnson and Johnson（U.S.）
• Merck KGaA（Germany）
• Novartis AG（Switzerland）
• Pfizer Inc.（U.S.）
• Takeda Pharmaceutical Company Limited（Japan）
• Biogen, Inc.（U.S.）
• LEO Pharma A/S（Denmark）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）

（注：上位5社のSWOT分析を提供予定）

第12章 付録

LIST OF TABLES

• Table 1 Global Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 2 Global Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 3 Global Biologic Drugs Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 4 Global TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 5 Global TNF Inhibitors Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 6 Global Infliximab Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 7 Global Adalimumab Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 8 Global Etanercept Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 9 Global Other TNF Inhibitors Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 10 Global Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 11 Global Interleukin Inhibitors Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 12 Global Guselkumab Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 13 Global Tildrakizumab Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 14 Global Other Biologic Drugs Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 15 Global Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 16 Global Topical Treatment Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 17 Global Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 18 Global Corticosteroids Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 19 Global Desonide Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 20 Global Betamethasone Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 21 Global Etanercept Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 22 Global Other Cortocisteroids Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 23 Global Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 24 Global Vitamin D Analogs Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 25 Global Calcitriol Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 26 Global Calcipotriol Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 27 Global Tacalcitol Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 28 Global Retinoids Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 29 Global Calcineurin Inhibitors Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 30 Global Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 31 Global Systemic Treatments Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 32 Global Methotrexate Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 33 Global Cyclosporine Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 34 Global Other Systemic Treatments Market for Psoriasis, by Country/Region, 2022-2031 (USD Million)
• Table 35 Global Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 36 Global Plaque Psoriasis Treatment Market, by Country/Region, 2022-2031 (USD Million)
• Table 37 Global Psoriatic Arthritis Treatment Market, by Country/Region, 2022-2031 (USD Million)
• Table 38 Global Other Psoriasis Treatment Market, by Country/Region, 2022-2031 (USD Million)
• Table 39 Global Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 40 Global Psoriasis Treatment Market for Oral Administration, by Country/Region, 2022-2031 (USD Million)
• Table 41 Global Psoriasis Treatment Market for Topical Administration, by Country/Region, 2022-2031 (USD Million)
• Table 42 Global Psoriasis Treatment Market for Injectable Administration, by Country/Region, 2022-2031 (USD Million)
• Table 43 Global Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 44 Global Psoriasis Treatment Market for Hospital Pharmacies, by Country/Region, 2022-2031 (USD Million)
• Table 45 Global Psoriasis Treatment Market for Retail Pharmacies, by Country/Region, 2022-2031 (USD Million)
• Table 46 Global Psoriasis Treatment Market for Online/E-commerce Platforms, by Country/Region, 2022-2031 (USD Million)
• Table 47 Global Psoriasis Treatment Market, by Country/Region, 2022-2031 (USD Million)
• Table 48 North America: Psoriasis Treatment Market, by Country, 2022-2031 (USD Million)
• Table 49 North America: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 50 North America: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 51 North America: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 52 North America: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 53 North America: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 54 North America: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 55 North America: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 56 North America: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 57 North America: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 58 North America: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 59 North America: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 60 U.S.: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 61 U.S.: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 62 U.S.: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 63 U.S.: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 64 U.S.: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 65 U.S.: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 66 U.S.: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 67 U.S.: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 68 U.S.: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 69 U.S.: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 70 U.S.: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 71 Canada: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 72 Canada: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 73 Canada: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 74 Canada: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 75 Canada: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 76 Canada: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 77 Canada: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 78 Canada: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 79 Canada: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 80 Canada: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 81 Canada: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 82 Europe: Psoriasis Treatment Market, by Country/Region, 2022-2031 (USD Million)
• Table 83 Europe: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 84 Europe: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 85 Europe: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 86 Europe: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 87 Europe: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 88 Europe: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 89 Europe: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 90 Europe: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 91 Europe: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 92 Europe: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 93 Europe: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 94 Germany: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 95 Germany: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 96 Germany: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 97 Germany: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 98 Germany: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 99 Germany: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 100 Germany: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 101 Germany: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 102 Germany: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 103 Germany: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 104 Germany: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 105 France: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 106 France: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 107 France: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 108 France: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 109 France: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 110 France: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 111 France: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 112 France: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 113 France: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 114 France: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 115 France: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 116 U.K.: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 117 U.K.: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 118 U.K.: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 119 U.K.: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 120 U.K.: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 121 U.K.: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 122 U.K.: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 123 U.K.: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 124 U.K.: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 125 U.K.: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 126 U.K.: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 127 Italy: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 128 Italy: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 129 Italy: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 130 Italy: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 131 Italy: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 132 Italy: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 133 Italy: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 134 Italy: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 135 Italy: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 136 Italy: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 137 Italy: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 138 Spain: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 139 Spain: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 140 Spain: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 141 Spain: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 142 Spain: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 143 Spain: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 144 Spain: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 145 Spain: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 146 Spain: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 147 Spain: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 148 Spain: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 149 Netherlands: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 150 Netherlands: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 151 Netherlands: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 152 Netherlands: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 153 Netherlands: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 154 Netherlands: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 155 Netherlands: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 156 Netherlands: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 157 Netherlands: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 158 Netherlands: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 159 Netherlands: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 160 Switzerland: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 161 Switzerland: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 162 Switzerland: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 163 Switzerland: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 164 Switzerland: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 165 Switzerland: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 166 Switzerland: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 167 Switzerland: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 168 Switzerland: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 169 Switzerland: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 170 Switzerland: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 171 Poland: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 172 Poland: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 173 Poland: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 174 Poland: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 175 Poland: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 176 Poland: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 177 Poland: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 178 Poland: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 179 Poland: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 180 Poland: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 181 Poland: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 182 Rest of Europe: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 183 Rest of Europe: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 184 Rest of Europe: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 185 Rest of Europe: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 186 Rest of Europe: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 187 Rest of Europe: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 188 Rest of Europe: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 189 Rest of Europe: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 190 Rest of Europe: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 191 Rest of Europe: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 192 Rest of Europe: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 193 Asia-Pacific: Psoriasis Treatment Market, by Country/Region, 2022-2031 (USD Million)
• Table 194 Asia-Pacific: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 195 Asia-Pacific: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 196 Asia-Pacific: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 197 Asia-Pacific: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 198 Asia-Pacific: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 199 Asia-Pacific: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 200 Asia-Pacific: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 201 Asia-Pacific: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 202 Asia-Pacific: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 203 Asia-Pacific: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 204 Asia-Pacific: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 205 China: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 206 China: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 207 China: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 208 China: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 209 China: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 210 China: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 211 China: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 212 China: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 213 China: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 214 China: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 215 China: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 216 India: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 217 India: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 218 India: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 219 India: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 220 India: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 221 India: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 222 India: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 223 India: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 224 India: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 225 India: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 226 India: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 227 Japan: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 228 Japan: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 229 Japan: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 230 Japan: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 231 Japan: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 232 Japan: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 233 Japan: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 234 Japan: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 235 Japan: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 236 Japan: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 237 Japan: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 238 Australia: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 239 Australia: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 240 Australia: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 241 Australia: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 242 Australia: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 243 Australia: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 244 Australia: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 245 Australia: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 246 Australia: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 247 Australia: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 248 Australia: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 249 New Zealand: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 250 New Zealand: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 251 New Zealand: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 252 New Zealand: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 253 New Zealand: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 254 New Zealand: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 255 New Zealand: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 256 New Zealand: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 257 New Zealand: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 258 New Zealand: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 259 New Zealand: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 260 Rest of Asia-Pacific: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 261 Rest of Asia-Pacific: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 262 Rest of Asia-Pacific: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 263 Rest of Asia-Pacific: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 264 Rest of Asia-Pacific: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 265 Rest of Asia-Pacific: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 266 Rest of Asia-Pacific: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 267 Rest of Asia-Pacific: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 268 Rest of Asia-Pacific: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 269 Rest of Asia-Pacific: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 270 Rest of Asia-Pacific: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 271 Latin America: Psoriasis Treatment Market, by Country/Region, 2022-2031 (USD Million)
• Table 272 Latin America: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 273 Latin America: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 274 Latin America: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 275 Latin America: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 276 Latin America: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 277 Latin America: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 278 Latin America: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 279 Latin America: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 280 Latin America: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 281 Latin America: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 282 Latin America: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 283 Brazil: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 284 Brazil: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 285 Brazil: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 286 Brazil: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 287 Brazil: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 288 Brazil: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 289 Brazil: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 290 Brazil: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 291 Brazil: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 292 Brazil: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 293 Brazil: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 294 Mexico: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 295 Mexico: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 296 Mexico: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 297 Mexico: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 298 Mexico: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 299 Mexico: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 300 Mexico: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 301 Mexico: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 302 Mexico: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 303 Mexico: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 304 Mexico: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 305 Rest of Latin America: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 306 Rest of Latin America: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 307 Rest of Latin America: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 308 Rest of Latin America: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 309 Rest of Latin America: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 310 Rest of Latin America: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 311 Rest of Latin America: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 312 Rest of Latin America: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 313 Rest of Latin America: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 314 Rest of Latin America: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 315 Rest of Latin America: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 316 Middle East & Africa: Psoriasis Treatment Market, by Treatment Type, 2022-2031 (USD Million)
• Table 317 Middle East & Africa: Biologic Drugs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 318 Middle East & Africa: TNF Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 319 Middle East & Africa: Interleukin Inhibitors Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 320 Middle East & Africa: Topical Treatment Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 321 Middle East & Africa: Corticosteroids Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 322 Middle East & Africa: Vitamin D Analogs Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 323 Middle East & Africa: Systemic Treatments Market for Psoriasis, by Type, 2022-2031 (USD Million)
• Table 324 Middle East & Africa: Psoriasis Treatment Market, by Disease Type, 2022-2031 (USD Million)
• Table 325 Middle East & Africa: Psoriasis Treatment Market, by Administration Route, 2022-2031 (USD Million)
• Table 326 Middle East & Africa: Psoriasis Treatment Market, by Distribution Channel, 2022-2031 (USD Million)
• Table 327 Recent Developments, by Company, 2021-2023

LIST OF FIGURES

• Figure 1 Research Process
• Figure 2 Secondary Sources Referenced for This Study
• Figure 3 Primary Research Techniques
• Figure 4 Key Executives Interviewed
• Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
• Figure 6 Market Sizing and Growth Forecast Approach
• Figure 7 Global Psoriasis Treatment Market, by Treatment Type, 2024 Vs.2031 (USD Million)
• Figure 8 Global Psoriasis Treatment Market, by Disease Type, 2024 Vs.2031 (USD Million)
• Figure 9 Global Psoriasis Treatment Market, by Administration Route, 2024 Vs.2031 (USD Million)
• Figure 10 Global Psoriasis Treatment Market, by Distribution Channel, 2024 Vs.2031 (USD Million)
• Figure 11 Global Psoriasis Treatment Market, by Geography
• Figure 12 Impact Analysis of Market Dynamics
• Figure 13 Global Psoriasis Treatment Market, by Treatment Type, 2024 Vs.2031 (USD Million)
• Figure 14 Global Psoriasis Treatment Market, by Disease Type, 2024 Vs.2031 (USD Million)
• Figure 15 Global Psoriasis Treatment Market, by Administration Route, 2024 Vs.2031 (USD Million)
• Figure 16 Global Psoriasis Treatment Market, by Distribution Channel, 2024 Vs.2031 (USD Million)
• Figure 17 North America: Psoriasis Treatment Market Snapshot
• Figure 18 Europe: Psoriasis Treatment Market Snapshot
• Figure 19 Asia-Pacific: Psoriasis Treatment Market Snapshot
• Figure 20 Latin America: Psoriasis Treatment Market Snapshot
• Figure 21 Key Growth Strategies Adopted by Leading Players (2021-2024)
• Figure 22 Psoriasis Treatment Market: Competitive Benchmarking, by Treatment Type
• Figure 23 Psoriasis Treatment Market: Competitive Benchmarking, by Region
• Figure 24 Psoriasis Treatment Market: Competitive Dashboard
• Figure 25 Global Psoriasis Treatment Market: Market Share/Market Ranking Analysis, by Key Players, 2023
• Figure 26 AbbVie Inc.: Financial Overview (2023)
• Figure 27 AstraZeneca Plc: Financial Overview (2023)
• Figure 28 Boehringer Ingelheim: Financial Overview (2023)
• Figure 29 Eli Lilly and Company: Financial Overview (2023)
• Figure 30 Johnson and Johnson: Financial Overview (2023)
• Figure 31 Merck KGaA: Financial Overview (2023)
• Figure 32 Novartis AG: Financial Overview (2023)
• Figure 33 Pfizer Inc.: Financial Overview (2023)
• Figure 34 Takeda Pharmaceutical Company Limited: Financial Overview (2023)
• Figure 35 Biogen, Inc.: Financial Overview (2023)
• Figure 36 Sun Pharmaceutical Industries Ltd.: Financial Overview (2023)
• Figure 37 Dr. Reddy's Laboratories Ltd.: Financial Overview (2023)

Psoriasis Treatment Market Size, Share, Forecast, & Trends Analysis By Treatment (TNF Inhibitor, Interleukin, Corticosteroids, Calcitriol, Retinoids, Calcineurin, Methotrexate) Disease (Plaque Psoriasis, Psoriatic Arthritis) - Global Forecast to 2031

The psoriasis treatment market is expected to reach $35.07 billion by 2031, at a CAGR of 9.8% from 2024 to 2031.

Following thorough secondary and primary research and in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, challenges, opportunities, and trends.

The growth of this market is driven by factors such as the high burden of psoriasis, advancements in treatment options & diagnosis methods, a better understanding of disease pathogenesis, and the rising prevalence of psoriasis among the aging population. Additionally, increasing awareness of psoriasis, the rising utilization of combination therapies, and ongoing research on psoriasis are expected to create market growth opportunities.

Based on treatment type, the market is segmented into biologic drugs, topical treatments, and systemic treatments. The biologics drugs segment is projected to witness the highest growth rate of 7.4% during the forecast period of 2024-2031. The growth of this segment is driven by the increasing adoption of Interleukin inhibitors over conventional systemic medications due to their enhanced effectiveness and improved safety profile. Additionally, ongoing advancements in biologic drugs and initiatives by market players to introduce new biologic treatments for psoriasis are contributing to the segment's growth. For instance, in March 2023, Eli Lilly and Company (U.S.) launched Copellor, an interleukin inhibitor specifically designed for treating psoriasis, in India.

Based on disease type, the psoriasis treatment market is segmented into plaque psoriasis, psoriatic arthritis, and others. The psoriatic arthritis segment is expected to record the highest CAGR during the forecast period of 2024-2031. This segment's growth is driven by the increasing prevalence of psoriatic arthritis among patients with plaque psoriasis, growing awareness about the condition, and advancements in treatment for managing the disease.

Based on administration route, the global psoriasis treatment market is segmented into oral, topical, and injectable. The injectable segment is projected to register the highest CAGR during the forecast period of 2024-2031. This segment is driven by the increasing adoption of biologic therapies, which are mainly administered via injections, advancements in injection technology such as prefilled syringes and autoinjectors, and the increasing availability and accessibility of injectable medications through various distribution channels, including specialty pharmacies and online platforms.

Based on distribution channel, the global psoriasis treatment market is segmented into hospital pharmacies, retail pharmacies, and online/e-commerce platforms. The online/e-commerce platforms segment is expected to register the highest CAGR during the forecast period. This growth can be attributed to the proliferation of e-commerce platforms, the rapid pace of digitalization, and the convenience of online shopping. These platforms provide a wide range of products, enabling patients to easily compare prices, read reviews, and access information about various treatment options.

An in-depth analysis of the geographical scenario of the psoriasis treatment market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the global psoriasis treatment market, followed by Europe and Asia-Pacific. North America's significant market share can be attributed to the high prevalence of psoriasis, widespread adoption of personalized therapies, advanced health infrastructure, and ongoing research and development efforts focused on psoriasis. These efforts have resulted in new treatment approaches and drugs being continuously developed and introduced to the market.

Key companies operating in the global psoriasis treatment market are AbbVie Inc. (U.S.), AstraZenca Plc (U.K.), Boehringer Ingelheim (Germany), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Johnson and Johnson (U.S.), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Biogen, Inc. (U.S.), LEO Pharma A/S (Denmark), Sun Pharmaceutical Industries Ltd. (India), and Dr. Reddy's Laboratories Ltd. (India).

Scope of the Report:

Psoriasis Treatment Market Assessment-by Treatment Type

• Biologic Drugs
  • TNF Inhibitors
• Infliximab
• Adalimumab
• Etanercept
• Other TNF Inhibitors
  • Interleukin Inhibitors
• Guselkumab
• Risankizumab
• Tildrakizumab
  • Other Biologic Drugs (Anakinra, Basiliximab, Daclizumab, and Briakinumab, among others)
• Topical Treatments
  • Corticosteroids
• Hydrocortisone
• Desonide
• Betamethasone
• Other Corticosteroids
  • Vitamin D Analogs
• Calcitriol
• Calcipotriol
• Tacalcitol
  • Retinoids
  • Calcineurin Inhibitors
• Systemic Treatments
  • Methotrexate
  • Cyclosporine
  • Acitretin
  • Other Systemic Drugs (Apremilast, Cyclosporine, Adalimumab, Ustekinumab, Etanercept, Tofacitinib, and Tildrakizumab, among others)

Psoriasis Treatment Market Assessment-by Disease Type

• Plaque Psoriasis
• Psoriatic Arthritis
• Other Psoriasis Types (Guttate Psoriasis, Pustular Psoriasis, Inverse Psoriasis, and Erythrodermic Psoriasis)

Psoriasis Treatment Market Assessment-by Administration Route

• Oral
• Topical
• Injectable

Psoriasis Treatment Market Assessment-by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online/E-commerce Platforms

Psoriasis Treatment Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Poland
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • Rest of Asia-Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa

TABLE OF CONTENTS

1. Overview

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency and Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Drivers
    • 4.2.1.1. High Burden of Psoriasis
    • 4.2.1.2. Advancements in Treatment Options
    • 4.2.1.3. Improved Psoriasis Diagnosis
    • 4.2.1.4. Elderly People More Susceptible to Psoriasis
  • 4.2.2. Restraints
    • 4.2.2.1. High Costs of Psoriasis Treatments
    • 4.2.2.2. Side Effects of Medications
  • 4.2.3. Opportunities
    • 4.2.3.1. Rising Awareness Regarding Psoriasis
    • 4.2.3.2. Growing Use of Combination Therapies for Treatment
    • 4.2.3.3. Growing Research Regarding Psoriasis
  • 4.2.4. Challenges
    • 4.2.4.1. Stringent Regulatory & Approval Process of Drugs
• 4.3. Trends
  • 4.3.1. Targeted Therapies
  • 4.3.2. Steroid-free Topicals
• 4.4. Factor Analysis
• 4.5. Product Pipeline Analysis
• 4.6. Regulatory Analysis
• 4.7. Porter's Five Forces Analysis
• 4.8. Fundings & Investments Analysis

5. Psoriasis Treatment Market Assessment-by Test Type

• 5.1. Overview
• 5.2. Biologic Drugs
  • 5.2.1. TNF Inhibitors
    • 5.2.1.1. Infliximab
    • 5.2.1.2. Adalimumab
    • 5.2.1.3. Etanercept
    • 5.2.1.4. Other TNF Inhibitors
  • 5.2.2. Interleukin Inhibitors
    • 5.2.2.1. Guselkumab
    • 5.2.2.2. Risankizumab
    • 5.2.2.3. Tildrakizumab
  • 5.2.3. Other Biologic Drugs
• 5.3. Topical Treatments
  • 5.3.1. Corticosteroids
    • 5.3.1.1. Hydrocortisone
    • 5.3.1.2. Desonide
    • 5.3.1.3. Betamethasone
    • 5.3.1.4. Other Corticosteroids
  • 5.3.2. Vitamin D Analogs
    • 5.3.2.1. Calcitrol
    • 5.3.2.2. Calcipotriol
    • 5.3.2.3. Tacalcitol
  • 5.3.3. Retinoids
  • 5.3.4. Calcineurin Inhibitors
• 5.4. Systemic Treatments
  • 5.4.1. Methotrexate
  • 5.4.2. Cyclosporine
  • 5.4.3. Acitretin
  • 5.4.4. Other Systemic Treatments

6. Psoriasis Treatment Market Assessment-by Disease Type

• 6.1. Overview
• 6.2. Plaque Psoriasis
• 6.3. Psoriatic Arthritis
• 6.4. Other Types

7. Psoriasis Treatment Market Assessment-by Administration Route

• 7.1. Overview
• 7.2. Oral
• 7.3. Topical
• 7.4. Injectable

8. Psoriasis Treatment Market Assessment- by Distribution Channel

• 8.1. Overview
• 8.2. Hospital Pharmacies
• 8.3. Retail Pharmacies
• 8.4. Online/E-commerce Platforms

9. Psoriasis Treatment Market Assessment-by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. France
  • 9.3.3. U.K.
  • 9.3.4. Italy
  • 9.3.5. Spain
  • 9.3.6. Netherlands
  • 9.3.7. Switzerland
  • 9.3.8. Poland
  • 9.3.9. Rest of Europe
• 9.4. Asia-Pacific
  • 9.4.1. China
  • 9.4.2. India
  • 9.4.3. Japan
  • 9.4.4. Australia
  • 9.4.5. New Zealand
  • 9.4.6. Rest of Asia-Pacific
• 9.5. Latin America
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America
• 9.6. Middle East & Africa

10. Competition Analysis

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Benchmarking
• 10.4. Competitive Dashboard
  • 10.4.1. Industry Leaders
  • 10.4.2. Market Differentiators
  • 10.4.3. Vanguards
  • 10.4.4. Emerging Companies
• 10.5. Market Share Analysis/ Market Ranking Analysis, by Key Players (2023)

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

• 11.1. AbbVie Inc. (U.S.)
• 11.2. AstraZenca Plc (U.K.)
• 11.3. Boehringer Ingelheim (Germany)
• 11.4. Celgene Corporation (U.S.)
• 11.5. Eli Lilly and Company (U.S.)
• 11.6. Johnson and Johnson (U.S.)
• 11.7. Merck KGaA (Germany)
• 11.8. Novartis AG (Switzerland)
• 11.9. Pfizer Inc. (U.S.)
• 11.10. Takeda Pharmaceutical Company Limited (Japan)
• 11.11. Biogen, Inc. (U.S.)
• 11.12. LEO Pharma A/S (Denmark)
• 11.13. Sun Pharmaceutical Industries Ltd. (India)
• 11.14. Dr. Reddy's Laboratories Ltd. (India)

(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

12. Appendix

• 12.1. Available Customization
• 12.2. Related Reports